Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors

Premature discontinuation of aromatase inhibitors (AIs) in breast cancer survivors compromises treatment outcomes. We aimed to evaluate whether patient-reported joint pain predicts premature discontinuation of AIs.